Michael H.
- Country
- Germany
- Department
- n/a
Research Overview
- Efficacy and Safety of Inhaled Treprostinil Liposome in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)
- A Phase 3, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Levosimendan in Patients with Pulmonary Hypertension and HFpEF
- A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease.
Data & Insights
Has run more than one trial at 138 of 212 partner sites.
Specializations
Pulmonary Arterial Hypertension
This investigator specializes in conducting research on pulmonary arterial hypertension (PAH), with particular focus on evaluating novel therapeutic approaches and treatment combinations. Their work encompasses studies of innovative medications including inhaled imatinib, seralutinib, and sotatercept.
- Treatment optimization strategies
- Long-term therapeutic outcomes
- Novel drug delivery systems
Specialized Pulmonary Conditions
The investigator studies complex variants of pulmonary hypertension, including combined postcapillary and precapillary pulmonary hypertension and pulmonary hypertension associated with chronic obstructive pulmonary disease.
- Pulmonary vascular disease
- Heart failure with preserved ejection fraction
- Interstitial lung disease complications
Treatment Approaches
Research focuses on evaluating various therapeutic interventions including oral inhalation treatments, parenteral therapies, and combination treatment strategies.
- Triple therapy combinations
- Inhalation powder formulations
- Long-term extension studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.